Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

15.83
-0.2700-1.68%
Post-market: 15.43-0.4000-2.53%19:30 EDT
Volume:921.17K
Turnover:14.68M
Market Cap:874.52M
PE:-5.74
High:16.91
Open:16.32
Low:15.33
Close:16.10
52wk High:16.93
52wk Low:5.97
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.45
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:2.15
PE(LYR):-6.54

Loading ...

4D Molecular Therapeutics Posts Strong 4D-150 Trial Results

TIPRANKS
·
Jul 20

4D Molecular Therapeutics Reports Positive 2-year Phase 2b PRISM Data for 4d-150 in Wet AMD

Reuters
·
Jul 20

4D Molecular Therapeutics Price Target Maintained with a $36.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 20

4D Molecular Therapeutics Reports Positive 2-year Phase 2b PRISM Data for 4d-150 in Wet AMD

Reuters
·
Jul 19

4D Molecular Therapeutics - 4d-150 Continues to be Well Tolerated with no New Safety Findings

THOMSON REUTERS
·
Jul 19

4dmt Announces Positive 2-year Data from Prism Phase 2B Clinical Trial in a Broad Wet Amd Population

THOMSON REUTERS
·
Jul 19

Press Release: 4DMT Announces New Employment Inducement Grants

Dow Jones
·
Jul 18

4D Molecular Therapeutics CEO David Kirn Sells USD 739,829 in Common Shares

Reuters
·
Jul 15

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of 6,566 Common Shares Valued at $91,924

Reuters
·
Jul 03

4D Molecular Therapeutics to Present 2-year PRISM Phase 2b Data for 4d-150 Gene Therapy in Neovascular AMD at ASRS 2026

Reuters
·
Jul 01

Morgan Stanley Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Jun 30

4D Molecular Therapeutics Buy Rating Reaffirmed on 4D-150 Pivotal Trial Momentum; Price Target Maintained at $36

TIPRANKS
·
Jun 30

4D Molecular Therapeutics Shares Rise After New Credit Facility

Dow Jones
·
Jun 29

4D Molecular Therapeutics Secures $200 Million Loan Facility

TIPRANKS
·
Jun 29

4D Molecular completes enrollment in 4FRONT-2 trial

TIPRANKS
·
Jun 29

4D Molecular Therapeutics Completes Enrollment for Phase 3 4d-150 Wet AMD Trial 4front-2

Reuters
·
Jun 29

4D Molecular Therapeutics - 4front-2 Over-enrolled with Anticipated N>500; Final Randomization Expected in Q3 2026

THOMSON REUTERS
·
Jun 29

4D Molecular Therapeutics - 4front-2 52-week Topline Data Expected in H2 2027

THOMSON REUTERS
·
Jun 29

4dmt Completes Enrollment for 4front-2 Global Phase 3 Clinical Trial of 4d-150 in Wet Amd

THOMSON REUTERS
·
Jun 29

4dmt Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

THOMSON REUTERS
·
Jun 29